Arch Pharmalabs
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Weaknesses
5- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -10.3% over past five years.
- Company has a low return on equity of -18.5% over last 3 years.
- Company has high debtors of 911 days.
- Working capital days have increased from 674 days to 1,485 days
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 160 | 179 | 165 | 143 | 162 | 172 | 153 | 159 | 137 | 164 | 198 | 155 |
| Expenses | 146 | 155 | 164 | 159 | 131 | 154 | 164 | 149 | 150 | 228 | 158 | 191 | 162 |
| Operating Profit | 2.87 | 4.61 | 14.76 | 6.51 | 12.54 | 8.29 | 7.87 | 4.15 | 8.62 | -91.75 | 5.77 | 6.78 | -6.31 |
| OPM % | 1.93% | 2.88% | 8.26% | 3.94% | 8.74% | 5.11% | 4.58% | 2.71% | 5.42% | -67.11% | 3.53% | 3.43% | -4.06% |
| Other Income | 17.47 | 20.21 | 7.04 | 14.1 | 9.13 | 16.07 | 13.11 | 15.9 | 10.75 | 103 | 12.06 | 11.95 | 22.43 |
| Interest | 8.76 | 9.76 | 9.54 | 8.38 | 7.8 | 7.12 | 7.84 | 6.7 | 6.3 | 6.34 | 4.41 | 4.36 | 3.91 |
| Depreciation | 7.22 | 7.36 | 8.33 | 8.12 | 8.48 | 8.51 | 8.76 | 8.87 | 8.9 | 8.99 | 8.96 | 8.97 | 9 |
| PBT | 4.36 | 7.7 | 3.93 | 4.11 | 5.39 | 8.73 | 4.38 | 4.48 | 4.17 | -4.35 | 4.46 | 5.4 | 3.21 |
| Tax % | 28.67% | 17.79% | 30.03% | 29.68% | 26.16% | 13.4% | 29.45% | 29.69% | 36.45% | -57.01% | 31.84% | 29.81% | 42.37% |
| Net Profit | 3.12 | 6.33 | 2.75 | 2.89 | 3.98 | 7.56 | 3.1 | 3.15 | 2.65 | -1.87 | 3.05 | 3.78 | 1.85 |
| EPS (₹) | 0.03 | 0.07 | 0.03 | 0.03 | 0.04 | 0.08 | 0.03 | 0.03 | 0.03 | -0.02 | 0.03 | 0.04 | 0.02 |
Profit & Loss
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 |
|---|---|---|---|---|---|---|---|
| Sales | 539 | 981 | 1,162 | 1,425 | 1,771 | 2,265 | 569 |
| Expenses | 437 | 805 | 897 | 1,077 | 1,321 | 2,016 | 626 |
| Operating Profit | 102 | 176 | 264 | 348 | 450 | 248 | -57 |
| OPM % | 19% | 18% | 23% | 24% | 25% | 11% | -10% |
| Other Income | 4 | 0 | 7 | 6 | 22 | 13 | 2 |
| Interest | 38 | 82 | 143 | 167 | 242 | 307 | 332 |
| Depreciation | 18 | 33 | 52 | 66 | 84 | 96 | 104 |
| PBT | 50 | 61 | 76 | 122 | 146 | -141 | -491 |
| Tax % | 28% | 30% | 27% | 29% | 27% | 10% | -13% |
| Net Profit | 35 | 43 | 56 | 87 | 106 | -154 | -428 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 25 | 25 | 28 | 28 |
| Reserves | 325 | 362 | 443 | 650 | 750 | 751 | 1,307 |
| Borrowings | 420 | 954 | 1,248 | 1,382 | 1,615 | 2,386 | 3,145 |
| Other Liabilities | 103 | 257 | 322 | 441 | 678 | 847 | 472 |
| Total Liabilities | 869 | 1,594 | 2,035 | 2,498 | 3,067 | 4,012 | 4,952 |
| Fixed Assets | 301 | 529 | 645 | 768 | 848 | 921 | 1,795 |
| CWIP | 32 | 135 | 97 | 30 | 63 | 34 | 31 |
| Investments | 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 518 | 930 | 1,293 | 1,699 | 2,156 | 3,057 | 3,125 |
| Total Assets | 869 | 1,594 | 2,035 | 2,498 | 3,067 | 4,012 | 4,952 |
Cash Flow
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 |
|---|---|---|---|---|---|---|---|
| Operating | — | -183 | -17 | 187 | 239 | -447 | -511 |
| Investing | — | -339 | -132 | -262 | -187 | -150 | -2 |
| Financing | — | 466 | 169 | 77 | -25 | 630 | 426 |
| Net Cash Flow | — | -55 | 20 | 1 | 27 | 33 | -86 |
| Free Cash Flow | — | -540 | -142 | -68 | 72 | -609 | -514 |
| CFO/OP | — | -100 | -2 | 59 | 61 | -177 | 892 |
Ratios
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 132 | 168 | 153 | 152 | 189 | 911 |
| Inventory Days | 180 | 204 | 217 | 213 | 211 | 215 | 672 |
| Days Payable | 80 | 53 | 111 | 144 | 179 | 148 | 279 |
| Cash Conversion Cycle | 212 | 283 | 275 | 222 | 184 | 256 | 1,304 |
| Working Capital Days | 229 | 257 | 307 | 282 | 239 | 299 | 1,485 |
| ROCE % | — | 14% | 14% | 15% | 17% | 6% | -4% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Arch Pharmalabs insights
29 extracted metrics + investor summaries across FY08–FY26.
Documents
Frequently Asked Questions about Arch Pharmalabs
Where is Arch Pharmalabs Ltd (524729) listed?
Company Information
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524729.md for Arch Pharmalabs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.